Shares of Biotechnology company Masimo climbed 1.3% this morning. Here are some quick facts to get you started if you are interested in the stock:
-
Masimo has logged a -26.0% 52 week change, compared to 16.2% for the S&P 500
-
MASI has an average analyst rating of buy and is 18.08% away from its mean target price of $92.0 per share
-
Its trailing earnings per share (EPS) is $1.63, which brings its trailing Price to Earnings (P/E) ratio to 66.6. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $3.08 and its forward P/E ratio is 35.3
-
The company has a Price to Book (P/B) ratio of 4.5 in contrast to the Health Care sector's average P/B ratio is 4.08
-
MASI has reported YOY quarterly earnings growth of -71.4% and gross profit margins of 0.5%
-
The company's free cash flow for the last fiscal year was $-39500000 and the average free cash flow growth rate is -34.0%
-
Masimo's revenues have an average growth rate of 0.8% with operating expenses growing at 9.2%. The company's current operating margins stand at -24.3%